Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | BRS3 | P32247 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411727 | 0.87 | TGFBR1 (0.46) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL409228 | 0.87 | TGFBR1 (0.46) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL412449 | 0.85 | TGFBR1 (0.49) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL5919686 | 0.83 | MAT2A (0.46) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL5919625 | 0.83 | TGFBR1 (0.57) | TGFBR1MAPK14KDRRIPK2 | |
| SCHEMBL5919650 | 0.83 | TGFBR1 (0.55) | TGFBR1MAPK14KDR | |
| SCHEMBL411664 | 0.81 | TGFBR1 (0.55) | TGFBR1 | |
| SCHEMBL5919631 | 0.78 | TGFBR1 (0.56) | TGFBR1 | |
| SCHEMBL408704 | 0.74 | TGFBR1 (0.69) | TGFBR1MAPK14KDR | |
| SCHEMBL24022650 | 0.72 | CCR1 (0.56) | TGFBR1MAPK14BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | GELLIBERT FRANCOISE J | 2006-04-06 | — | — | US | claimed |
| EP-1530567-A1 | PYRIDINYL SUBSTITUTED (1,2,3,)TRIAZOLES AS INHIBITORS OF THE TGF-BETA SIGNALLING PATHWAY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-18 | — | — | EP | claimed |
| WO-2004013125-A1 | PYRIDINYL SUBSTITUTED (1,2,3,)TRIAZOLES AS INHIBITORS OF THE TGF-BETA SIGNALLING PATHWAY | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | claimed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | GELLIBERT FRANCOISE J | 2006-04-06 | — | — | US | disclosed |
| EP-1530567-A1 | PYRIDINYL SUBSTITUTED (1,2,3,)TRIAZOLES AS INHIBITORS OF THE TGF-BETA SIGNALLING PATHWAY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004013125-A1 | PYRIDINYL SUBSTITUTED (1,2,3,)TRIAZOLES AS INHIBITORS OF THE TGF-BETA SIGNALLING PATHWAY | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074244-A1 | Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway | SMAD3, TGFBR1, SMAD2 | TGFBR1 2/4885MAPK14 164/4885KDR 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.